ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mechanism of RNA circHIPK3 Involved in Resistance of Lung Cancer Cells to Gefitinib

Zhao, Yi; Zhang, Caiming; Tang, Haibo; Wu, Xiaomin; Qi, Qiugan*南方医科大学
Biomed Research International2022-4-19DOI: 10.1155/2022/4541918
3被引6阅读
引用收藏
分享

摘要

To study the mechanism of circular ribonucleic acid (RNA) circHIPK3 involved in the resistance of lung cancer cells to gefitinib, 110 patients with lung cancer were recruited as the research objects, and the tumor tissue and para-cancerous tissue of each patient's surgical specimens were collected and paraffinized to detect the expression of circHIPK3 in different tissues. Gefitinib drug-resistant cell line of lung cancer was constructed with gefitinib to detect cell apoptosis under different conditions. As a result, the relative expression of circHIPK3 in patients with tumor diameter no less than 3 cm was dramatically inferior to that in patients with tumor diameter less than 3 cm (P < 0.05). The relative expression of circHIPK3 in patients with TNM stage II/III was dramatically inferior to that in patients with tumor, node, and metastasis (TNM) stage I (P < 0.05). Expression of circHIPK3 in patients with lymph node metastasis was dramatically inferior to that in patients without lymph node metastasis (P < 0.05). Of the lung cancer tissues of patients with different TNM stages, only six patients had high expression, and the remaining 104 patients had low expression. Moreover, electrophoresis revealed that circHIPK3 can only be amplified in cDNA, but not in gDNA. Gefitinib-mediated apoptosis rate of lung cancer drug-resistant cell lines decreased notably. In summary, the circular RNA circHIPK3 may have a notably low expression in lung cancer tissues, whose low expression had a certain enhancement effect on the drug resistance of lung adenocarcinoma cells to gefitinib.

学科与关键词

关键词
CIRCULAR RNAPROMOTES PROGRESSIONEXPRESSIONADENOCARCINOMAPROLIFERATIONINVASIONGROWTH
相关
加载中…
  • A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells
    Fan, Daping; Yang, Yue; Zhang, Wei*BMC Pulmonary Medicine, 2022, 22(1): 27.被引 4
  • circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by regulating ABCB1
    Liang, Hongguang; Lin, Zelong; Lin, Huiwen; Zhao, Li; Huang, Weihua*Experimental and Therapeutic Medicine, 2021, 22(3): 934.被引 6
  • Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms
    Feng, Bing; Zhou, Hao; Wang, Ting; Lin, Xinrong; Lai, Yongting; Chu, Xiaoyuan; Wang, Rui*Frontiers in Cell and Developmental Biology, 2021, 9: 636913.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomed Research International
发表日期
2022-04-19
卷期
第 2022 卷
页码
4541918
DOI
10.1155/2022/4541918
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
CIK Cell Immunotherapy for Non-Small Cell Lung Cancer [2017ZC058]

作者

  • Z

    Zhao, Yi (第一作者)

    southern med univ

  • Z

    Zhang, Caiming

    southern med univ

查看全部 5 位作者收起作者
  • T

    Tang, Haibo

    southern med univ

  • W

    Wu, Xiaomin

    southern med univ

  • Q

    Qi, Qiugan (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417